About Alnylam Pharmaceuticals, Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Integration
Every way to get the Alnylam Pharmaceuticals, Inc logo
Same endpoint, same logo, resolved from whichever identifier your data already has. Pick one below to see the exact call -- SVG, PNG and WebP all come back from the same CDN-backed URL.
View full API docs<img src="https://api.logostream.dev/stocks/isin/US02043Q1076?key=YOUR_API_KEY&variant=logo"
alt="Alnylam Pharmaceuticals, Inc logo"
width="64" height="64" /><a href="https://logostream.dev">Logos provided by logostream</a>Why Use Our Stock Logo API?
Fast Delivery
<100ms response time via global CDN
Enterprise-Ready
99.99% uptime SLA with GDPR compliance
Multiple Formats
SVG, PNG, WebP - scalable to any size
400k+ Logos
Stocks, ETFs, Crypto, Banks, and more
Where to Use Stock Logos
Trading Platforms
Real-time stock displays with instant logo loading
Portfolio Apps
Visualize holdings with recognizable brand logos
Financial Dashboards
Enhance market data with company branding
News & Research
Illustrate articles with accurate company logos
Frequently Asked Questions
The Alnylam Pharmaceuticals, Inc logo is a trademark of its respective owner. logostream is not affiliated with Alnylam Pharmaceuticals, Inc and provides this logo for identification purposes only. Logo usage is subject to the trademark holder's brand guidelines -- see our Terms of Service for the attribution requirements that apply to the Logo API.
Need Stock Logos for Your Application?
Access 380,000+ company logos via our simple REST API. Perfect for trading platforms, portfolio apps, and financial dashboards.